InnDura Therapeutics develops novel immunotherapies utilizing _in vivo_ delivered mRNA technology. The company combines targeted Lipid Nanoparticles (LNPs) with its proprietary EVE16™ platform for therapeutic application. This approach focuses on engineering precise cellular responses for desired treatment outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer therapies often lack precision, leading to off-target effects and limiting their efficacy. This necessitates the development of more targeted approaches to minimize damage to healthy tissues and improve patient outcomes.
Solution
InnDura Therapeutics is developing targeted cancer therapies using its proprietary EVE16 engineering technology. This technology aims to enhance the precision of drug delivery, ensuring that therapeutic agents selectively target cancer cells while sparing healthy tissues. By focusing on clinical validation, InnDura seeks to demonstrate the efficacy and safety of its therapies, ultimately providing more effective and less toxic treatment options for cancer patients. The company's approach addresses the critical need for improved targeting in cancer therapeutics, potentially leading to better patient outcomes and reduced side effects.
Target Audience
The primary target audience includes cancer patients, oncologists, and pharmaceutical companies seeking more effective and targeted cancer treatment options.
Features
- EVE16 engineering technology for targeted drug delivery
- Focus on clinical validation to ensure efficacy and safety
- Development of therapies with enhanced precision